Pharma Criticizes Bioethics


Vienna - Oliver Huber, General Secretary of the Austrian industry association Pharmig, criticized the recent sharp increase in fees for the work of the ethics commissions for clinical trials. As a direct result of the new Medicines Law (AMG) in force since May 1, fees have almost tripled. Until recently a pharmaceutical company in Austria paid some Euro1,500. This has risen to Euro4,000 for the Lead Ethics Commission alone plus Euro700 for any further evaluation centre. “SME will not be able to afford clinical trials in Austria any longer. Should the present situation prevail pharmaceutical companies will prefer to go abroad, where clinical trials are much more economical,” forecasts Huber. In Germany companies pay around Euro1,500, in Great Britain Euro1,000, and in France Euro1,450.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues